What this Trial Is About

Precursor B cell acute lymphoblastic leukemia (B-ALL) is a fast-growing type of leukemia with a high chance of relapse and poor long-term survival in adults. Philadelphia chromosome positive (Ph+) ALL, caused by a specific chromosome translocation, is a common abnormality in this disease and accounts for about 30% of adult ALL cases. This research is a phase II, open-label study aiming to explore the safety and effectiveness of combining Venetoclax with Olverembatinib and Predinisone to improve survival outcomes for adults with newly diagnosed Ph+ B-ALL. Participants will receive a treatment regimen combining three drugs: Venetoclax, a BCL-2 inhibitor; Olverembatinib, a tyrosine kinase inhibitor; and Predinisone, a glucocorticoid. The study plans to enroll 36 participants to undergo this combination therapy in cycles lasting 28 days each, with the primary goal of assessing complete molecular response after three cycles. Throughout the study, participants will be closely monitored for treatment response and safety. Researchers will evaluate the molecular response at the end of the third treatment cycle to determine the level of disease control. The study includes assessments of participants' health status and side effects, with informed consent and ongoing follow-up to ensure safety and gather detailed information about the treatment effects.

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL